169 related articles for article (PubMed ID: 21264830)
1. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.
Han JY; Yoon KA; Park JH; Lee YJ; Lee GK; Han JH; Yoon SJ; Yun T; Kim HT; Lee JS
Cancer; 2011 Jul; 117(14):3201-8. PubMed ID: 21264830
[TBL] [Abstract][Full Text] [Related]
2. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.
Yin Z; Zhou B; He Q; Li M; Guan P; Li X; Cui Z; Xue X; Su M; Ma R; Bai W; Xia S; Jiang Y; Xu S; Lv Y; Li X
BMC Cancer; 2009 Dec; 9():439. PubMed ID: 20003463
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Lee YJ; Yoon KA; Han JY; Kim HT; Yun T; Lee GK; Kim HY; Lee JS
Clin Cancer Res; 2011 Aug; 17(15):5179-87. PubMed ID: 21653691
[TBL] [Abstract][Full Text] [Related]
4. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
5. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
6. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
7. The codon 399 Arg/Gln XRCC1 polymorphism is associated with lung cancer in Indians.
Natukula K; Jamil K; Pingali UR; Attili VS; Madireddy UR
Asian Pac J Cancer Prev; 2013; 14(9):5275-9. PubMed ID: 24175813
[TBL] [Abstract][Full Text] [Related]
8. SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.
Zhang L; Li QX; Wu HL; Lu X; Yang M; Yu SY; Yuan XL
Ann Oncol; 2014 Aug; 25(8):1584-90. PubMed ID: 24928833
[TBL] [Abstract][Full Text] [Related]
9. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract][Full Text] [Related]
10. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Liam CK; Ruthranesan M; Lee CH; Pang YK; Chua KT; Lim BK
Asia Pac J Clin Oncol; 2012 Sep; 8(3):267-74. PubMed ID: 22897510
[TBL] [Abstract][Full Text] [Related]
12. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Han JY; Park K; Kim SW; Lee DH; Kim HY; Kim HT; Ahn MJ; Yun T; Ahn JS; Suh C; Lee JS; Yoon SJ; Han JH; Lee JW; Jo SJ; Lee JS
J Clin Oncol; 2012 Apr; 30(10):1122-8. PubMed ID: 22370314
[TBL] [Abstract][Full Text] [Related]
13. The XRCC1 codon 399 Gln allele is associated with adenine to guanine p53 mutations in non-small cell lung cancer.
Casse C; Hu YC; Ahrendt SA
Mutat Res; 2003 Jul; 528(1-2):19-27. PubMed ID: 12873719
[TBL] [Abstract][Full Text] [Related]
14. ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma.
Jin H; Xie X; Wang H; Hu J; Liu F; Liu Z; Zhou J; Zhang Y; Xi X; Hu B; Liao Y; Tang J
PLoS One; 2014; 9(7):e101256. PubMed ID: 25025378
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Liao WY; Shih JY; Chang GC; Cheng YK; Yang JC; Chen YM; Yu CJ
J Thorac Oncol; 2012 Jun; 7(6):973-81. PubMed ID: 22551904
[TBL] [Abstract][Full Text] [Related]
16. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung.
Divine KK; Gilliland FD; Crowell RE; Stidley CA; Bocklage TJ; Cook DL; Belinsky SA
Mutat Res; 2001 Jan; 461(4):273-8. PubMed ID: 11104903
[TBL] [Abstract][Full Text] [Related]
17. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Bria E; Pilotto S; Amato E; Fassan M; Novello S; Peretti U; Vavalà T; Kinspergher S; Righi L; Santo A; Brunelli M; Corbo V; Giglioli E; Sperduti I; Milella M; Chilosi M; Scarpa A; Tortora G
Oncotarget; 2015 May; 6(14):12783-95. PubMed ID: 25904052
[TBL] [Abstract][Full Text] [Related]
18. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Xu C; Wang X; Zhang Y; Li L
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
[TBL] [Abstract][Full Text] [Related]
19. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Figg WD; Chau CH; Madan RA; Gulley JL; Gao R; Sissung TM; Spencer S; Beatson M; Aragon-Ching J; Steinberg SM; Dahut WL
Clin Genitourin Cancer; 2013 Sep; 11(3):229-37. PubMed ID: 23684781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
